121,463 Shares in Abrdn Life Sciences Investors (NYSE:HQL) Acquired by Wolverine Asset Management LLC

Wolverine Asset Management LLC bought a new stake in Abrdn Life Sciences Investors (NYSE:HQL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 121,463 shares of the company’s stock, valued at approximately $1,594,000. Wolverine Asset Management LLC owned approximately 0.44% of Abrdn Life Sciences Investors at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Ashton Thomas Securities LLC acquired a new stake in shares of Abrdn Life Sciences Investors during the 3rd quarter valued at $148,000. Kingswood Wealth Advisors LLC bought a new position in Abrdn Life Sciences Investors in the fourth quarter valued at about $160,000. Kapstone Financial Advisors LLC acquired a new stake in shares of Abrdn Life Sciences Investors during the third quarter valued at about $177,000. Sanctuary Advisors LLC grew its holdings in shares of Abrdn Life Sciences Investors by 11.4% during the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after purchasing an additional 1,355 shares during the last quarter. Finally, Stephens Inc. AR increased its stake in shares of Abrdn Life Sciences Investors by 7.6% in the third quarter. Stephens Inc. AR now owns 12,707 shares of the company’s stock valued at $192,000 after buying an additional 896 shares during the period. Institutional investors own 32.21% of the company’s stock.

Insider Activity

In related news, major shareholder Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock in a transaction on Friday, January 31st. The shares were sold at an average price of $14.27, for a total transaction of $216,090.61. Following the completion of the transaction, the insider now owns 3,381,371 shares of the company’s stock, valued at $48,252,164.17. This trade represents a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders sold 108,186 shares of company stock valued at $1,508,866. Company insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Trading Down 3.0 %

Shares of NYSE:HQL opened at $13.84 on Friday. Abrdn Life Sciences Investors has a 52 week low of $12.76 and a 52 week high of $15.90. The firm’s fifty day moving average is $13.74 and its 200-day moving average is $14.48.

Abrdn Life Sciences Investors Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, February 21st will be given a $0.47 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 13.58%.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.